Online citations, reference lists, and bibliographies.
← Back to Search

Prise En Charge Du Mésothéliome Pleural Malin En 2013

J. Margery, W. Gaspard, I. Ngampolo, H. Souhi, H. Floch, F. Riviere, C. Marotel, D. Planchard, F. Vaylet
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Resume Le mesotheliome malin pleural (MPM) est une tumeur rare et agressive, souvent consecutive a une exposition professionnelle a l’amiante. La symptomatologie clinique et radiologique est aspecifique. Le diagnostic est apporte par l’histologie a partir de biopsies pleurales obtenues par thoracoscopie. L’irradiation des orifices chirurgicaux diagnostiques est validee par les recommandations francophones. La chirurgie par pleuropneumonectomie elargie ou par pleurectomie/decortication n’est pas recommandee en dehors d’un essai clinique. La chimiotherapie par la combinaison pemetrexed-cisplatine est le traitement de reference du MPM. Le bevacizumab est evalue dans l’essai de phase III MAPS qui doit se terminer fin 2013.
This paper references
10.1183/09031936.00037310
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
A. Scherpereel (2010)
10.1016/j.athoracsur.2011.02.062
Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma.
J. Friedberg (2011)
10.2741/1953
WNT signaling in malignant mesothelioma.
S. Fox (2006)
10.1097/JTO.0b013e3182417da5
Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group
G. Levallet (2012)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1016/J.RMED.2006.10.018
Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
A. Scherpereel (2007)
10.1038/ng.855
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)
10.1073/PNAS.92.24.10854
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
A. Bianchi (1995)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1097/MCP.0b013e32812144bb
Biomarkers for mesothelioma
A. Scherpereel (2007)
10.1002/ijc.24711
Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005
N. Le Stang (2010)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1038/sj.bjc.6604442
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
10.1136/oem.2005.023200
The French National Mesothelioma Surveillance Program
M. Goldberg (2006)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1378/chest.08-2665
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
10.1183/09031936.00153611
Population-based survival for malignant mesothelioma after introduction of novel chemotherapy
R. Damhuis (2011)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1510/icvts.2010.255901
Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
S. Sharif (2011)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
10.1016/S0169-5002(02)00178-2
Inactivation of p16INK4a expression in malignant mesothelioma by methylation.
L. Wong (2002)
10.1510/icvts.2010.251488
A survey of opinions and beliefs concerning surgery for malignant pleural mesothelioma amongst 802 members of the European Association for Cardio-Thoracic Surgery (EACTS), the European Society of Thoracic Surgeons (ESTS) and the Society of Thoracic Surgeons (STS).
T. Treasure (2011)
10.1684/BDC.2008.0566
Cancer environnemental : le mésothéliome pleural
J. Margery (2008)
10.1097/JTO.0b013e3181ed0489
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2010)
10.1097/JTO.0b013e31815608d9
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
10.1016/S1556-0864(15)31509-4
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126.
G. Cole (2006)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/j.lungcan.2011.08.011
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
10.1200/JCO.2005.07.050
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
D. Fennell (2005)
10.1016/J.PNEUMO.2010.07.013
Traitement de seconde ligne dans le mésothéliome pleural malin. Étude rétrospective française (2005–2006)
J. Margery (2010)



Semantic Scholar Logo Some data provided by SemanticScholar